Shanghai Kaisen Biotechnology

Shanghai Kaisen Biotechnology is a clinical-stage biopharmaceutical company headquartered in the Zhangjiang Hi-Tech Park of Shanghai, China. The company specializes in the discovery and development of next-generation small molecule targeted therapies, primarily focusing on oncology and metabolic disorders. Its research engine is driven by a team of experienced scientists with backgrounds in global pharmaceutical companies, aiming to develop best-in-class or first-in-class drugs. Kaisen's lead program, KS-001, is a highly selective FGFR4 inhibitor designed to treat FGF19-overexpressing hepatocellular carcinoma. Beyond its lead asset, the company is advancing a pipeline of inhibitors targeting RET and KRAS mutations to address significant unmet needs in precision oncology.